DossierENTITY

P2X3 antagonist

Coverage of P2X3 antagonist in the Nexus archive.

Earliest in view: Jul 17 · 13:02 UTCMost recent: Jul 17 · 13:02 UTC

Co-mentioned in this coverage

American Society of Health-System Pharmacistsorganization1 GSKorganization1 Bellus Healthorganization1 camlipixanttopic1 Phase 3 trialstopic1 controlled substancestopic1 contrast agentstopic1

Recent coverage

HEALTHJul 17 · 13:02 UTCSTAT NEWS
STAT+: Pharmalittle: We’re reading about rising drug shortages, GSK coughing up a trial loss, and more
The U.S. experienced 227 active medication shortages in Q2 2026, with 48% being sole-source products and 10% involving life-saving contrast agents. GSK abandoned development of camlipixant, a chronic cough drug acquired for $2 billion, after Phase 3 trials showed limited efficacy.

P2X3 antagonist · Dossier · The Nexus